IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) CEO Yujiro Hata sold 26,338 shares of the company’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total value of $985,304.58. Following the transaction, the chief executive officer directly owned 690,695 shares in the company, valued at $25,838,899.95. The trade was a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
IDEAYA Biosciences Trading Down 0.6%
Shares of NASDAQ IDYA opened at $36.06 on Friday. The firm has a market capitalization of $3.17 billion, a PE ratio of -18.59 and a beta of -0.04. IDEAYA Biosciences, Inc. has a one year low of $26.05 and a one year high of $42.68. The business has a 50-day moving average price of $38.13 and a two-hundred day moving average price of $34.29.
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.The company had revenue of $8.86 million during the quarter, compared to analysts’ expectations of $8.02 million. During the same period last year, the company earned ($0.88) earnings per share. IDEAYA Biosciences’s revenue for the quarter was up 8800.0% compared to the same quarter last year. Research analysts anticipate that IDEAYA Biosciences, Inc. will post -4.38 EPS for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several equities analysts have recently commented on IDYA shares. Citigroup restated a “market outperform” rating on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a report on Tuesday, September 22nd. Wall Street Zen cut IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Truist Financial lowered their target price on IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Finally, Wedbush raised their price target on IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, IDEAYA Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.69.
Get Our Latest Stock Analysis on IDYA
IDEAYA Biosciences Company Profile
IDEAYA Biosciences, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights from tumor biology, cancer genetics and synthetic lethality to identify treatments designed to target specific molecular alterations in tumors.
Its development pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily in genetically defined cancers, including GNAQ- or GNA11-mutated uveal melanoma.
Read More
- Five stocks we like better than IDEAYA Biosciences
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
